|
Home
|
Molecular Imaging to Improve Diagnosis and Management of Disease |
|
Atreus is a development-stage, biopharmaceutical company headquartered in Cambridge, Mass. Atreus intends to develop two in-vivo radiopharmaceutical products suitable for Nuclear Medicine (SPECT) imaging and for PET imaging that will aid in the early diagnosis and management of diseases including rheumatoid arthritis. Earlier diagnosis can be crucial to effective treatment with disease modifying drugs which may prevent loss of function and result in improved quality of life for the patient.
Our mission is to develop proprietary molecular imaging products based on Annexin V, an endogenous human protein which binds to phosphatidylserine, a molecule expressed only on the surface of dead or dying cells (apoptotic and necrotic cells). Annexin, labeled with Technetium-99m (Tc-99m), a medical isotope widely used in diagnostic imaging, has been studied extensively in both animals and humans.
Tc-99m labelled Annexin has demonstrated the ability to image cellular apoptosis and necrosis – conditions associated with a variety of debilitating or fatal medical conditions including rheumatoid arthritis, Crohn’s disease, Alzheimer’s disease,, myocarditis, cardiac transplant rejection, acute myocardial infarction and unstable atherosclerotic carotid artery disease. In addition, Tc-99m labelled Annexin has been used to evaluate the response to treatment for lymphoma and lung cancer. |
|
|
